ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 075,68
0,99%
Dow Jones
38 923,27
0,18%
DAX
18 430,05
1,42%
Brent Oil
83,53
0,07%
Bitcoin
63 508,42
0,54%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Voyager Therapeutics Inc (VYGR)

  7. Voyager Therapeutics Inc (VYGR) Actualités

VYGR

Voyager Therapeutics (VYGR)

Voyager Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VYGR
DateHeureSourceTitreSymboleSociété
06/05/202413h00GlobeNewswire Inc.Voyager Therapeutics Announces First Quarter 2024 Conference Call and WebcastNASDAQ:VYGRVoyager Therapeutics Inc
22/04/202422h30GlobeNewswire Inc.Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual MeetingNASDAQ:VYGRVoyager Therapeutics Inc
16/04/202413h00GlobeNewswire Inc.Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone PaymentNASDAQ:VYGRVoyager Therapeutics Inc
26/03/202421h01GlobeNewswire Inc.Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VYGRVoyager Therapeutics Inc
13/03/202412h00GlobeNewswire Inc.Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical OfficerNASDAQ:VYGRVoyager Therapeutics Inc
28/02/202422h01GlobeNewswire Inc.Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating ResultsNASDAQ:VYGRVoyager Therapeutics Inc
28/02/202422h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VYGRVoyager Therapeutics Inc
26/02/202413h00GlobeNewswire Inc.Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone PaymentNASDAQ:VYGRVoyager Therapeutics Inc
22/02/202422h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VYGRVoyager Therapeutics Inc
21/02/202421h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VYGRVoyager Therapeutics Inc
21/02/202413h00GlobeNewswire Inc.Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and WebcastNASDAQ:VYGRVoyager Therapeutics Inc
20/02/202413h00GlobeNewswire Inc.Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late ResearchNASDAQ:VYGRVoyager Therapeutics Inc
07/02/202413h00GlobeNewswire Inc.Voyager Therapeutics to Present at the Oppenheimer Annual Life Sciences ConferenceNASDAQ:VYGRVoyager Therapeutics Inc
17/01/202422h20Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VYGRVoyager Therapeutics Inc
08/01/202422h04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VYGRVoyager Therapeutics Inc
05/01/202404h45GlobeNewswire Inc.Voyager Therapeutics Announces Pricing of Public OfferingNASDAQ:VYGRVoyager Therapeutics Inc
04/01/202422h14GlobeNewswire Inc.Voyager Therapeutics Announces Proposed Public OfferingNASDAQ:VYGRVoyager Therapeutics Inc
03/01/202413h00GlobeNewswire Inc.Voyager Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VYGRVoyager Therapeutics Inc
02/01/202413h46Dow Jones NewsVoyager Therapeutics Shares Leap Premarket on Novartis CollaborationNASDAQ:VYGRVoyager Therapeutics Inc
02/01/202413h00GlobeNewswire Inc.Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene TherapiesNASDAQ:VYGRVoyager Therapeutics Inc
06/12/202313h00GlobeNewswire Inc.Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy ProgramNASDAQ:VYGRVoyager Therapeutics Inc
06/11/202322h01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VYGRVoyager Therapeutics Inc
06/11/202322h01GlobeNewswire Inc.Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating ResultsNASDAQ:VYGRVoyager Therapeutics Inc
30/10/202312h00GlobeNewswire Inc.Voyager Therapeutics Announces Third Quarter 2023 Conference Call and WebcastNASDAQ:VYGRVoyager Therapeutics Inc
25/09/202313h00GlobeNewswire Inc.Voyager Therapeutics to Present at the Chardan Genetic Medicines ConferenceNASDAQ:VYGRVoyager Therapeutics Inc
30/08/202313h00GlobeNewswire Inc.Voyager Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:VYGRVoyager Therapeutics Inc
07/08/202314h00GlobeNewswire Inc.Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business OfficerNASDAQ:VYGRVoyager Therapeutics Inc
03/08/202313h00GlobeNewswire Inc.Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating ResultsNASDAQ:VYGRVoyager Therapeutics Inc
02/08/202313h00GlobeNewswire Inc.Voyager Therapeutics to Present at the Canaccord Genuity Growth ConferenceNASDAQ:VYGRVoyager Therapeutics Inc
27/07/202313h00GlobeNewswire Inc.Voyager Therapeutics Announces Second Quarter 2023 Conference Call and WebcastNASDAQ:VYGRVoyager Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VYGR

Dernières Valeurs Consultées

USI
USTECH100
US Tech 100
EU
AI
Air Liquide
COIN
BTCUSD
Bitcoin
EU
CAP
Capgemini
EU
CS
Axa
NYSE
KO
Coca Cola
EU
ACA
Credit Agricole
EU
RNO
Renault
EU
ML
Michelin
EU
GLE
Societe Generale
EU
BN
Danone
EU
LR
Legrand
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés